Sphingolipids in cancer: Regulation of pathogenesis and therapy

FEBS Letters

Volumn 580, Issue 23, 2006, Pages 5467-5476

  Ogretmen, Besim ^a  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Cancer; Ceramide; Chemoprevention; Chemotherapy; Drug resistance; Pathogenesis; Sphingolipid; Sphingosine

Indexed keywords

1 PHENYL 2 PALMITOYLAMINO 3 MORPHOLINO 1 PROPANOL; 2 OCTANOYLAMINOOCTADECADIENE 1,3 DIOL (4,6 DIENE CERAMIDE); ADAMANTYLCERAMIDE; ANTINEOPLASTIC AGENT; CERAMIDE; CERAMIDE DERIVATIVE; DAUNORUBICIN; DRONABINOL; FENRETINIDE; FINGOLIMOD; GAMMA TOCOPHEROL; GEMCITABINE; LIPOSOME; MONOCLONAL ANTIBODY; PEGINTERFERON; RESVERATROL; SAFINGOL; SERINOL; SPHINGOLIPID; SPHINGOMYELIN; SPHINGOSINE 1 PHOSPHATE ANTIBODY; UNCLASSIFIED DRUG; VINCRISTINE;

ACUTE LYMPHOCYTIC LEUKEMIA; CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER THERAPY; CARCINOGENESIS; CELL DEATH; CELL GROWTH; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; NONHUMAN; PRIORITY JOURNAL; SHORT SURVEY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; APOPTOSIS; DRUG RESISTANCE; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION; SPHINGOLIPIDS;

EID: 33749074473     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2006.08.052     Document Type: Short Survey

References (133)

1. Futerman A.H., and Hannun Y.A. The complex life of simple sphingolipids. EMBO Rep. 5 (2004) 777-782
2. Ogretmen B., and Hannun Y.A. Biologically active sphingolipids in cancer pathogenesis and treatment. Nat. Rev. Cancer 4 (2004) 604-616
3. Modrak D.E., Gold D.V., and Goldenberg D.M. Sphingolipid targets in cancer therapy. Mol. Cancer Ther. 5 (2006) 200-208
4. Kok J.W., and Sietsma H. Sphingolipid metabolism enzymes as targets for anticancer therapy. Curr. Drug Targets 5 (2004) 375-382
5. Reynolds C.P., Maurer B.J., and Kolesnick R.N. Ceramide synthesis and metabolism as a target for cancer therapy. Cancer Lett. 206 (2004) 169-180
6. Fox T.E., Finnegan C.M., Blumenthal R., and Kester M. The clinical potential of sphingolipid-based therapeutics. Cell Mol. Life Sci. 63 (2006) 1017-1023
7. Futerman A.H., and Riezman H. The ins and outs of sphingolipid synthesis. Trends Cell Biol. 15 (2005) 312-318
8. Hannun Y.A., and Luberto C. Lipid metabolism: ceramide transfer protein adds a new dimension. Curr. Biol. 14 (2004) R163-R165
9. Sundararaj K.P., et al. Rapid shortening of telomere length in response to ceramide involves the inhibition of telomere binding activity of nuclear glyceraldehyde-3-phosphate dehydrogenase. J. Biol. Chem. 279 (2004) 6152-6162
10. Ogretmen B., et al. Role of ceramide in mediating the inhibition of telomerase activity in A549 human lung adenocarcinoma cells. J. Biol. Chem. 276 (2001) 24901-24910
11. Ogretmen B., Kraveka J.M., Schady D., Usta J., Hannun Y.A., and Obeid L.M. Molecular mechanisms of ceramide-mediated telomerase inhibition in the A549 human lung adenocarcinoma cell line. J. Biol. Chem. 276 (2001) 32506-32514
12. Hahn W.C., Counter C.M., Lundberg A.S., Beijersbergen R.L., Brooks M.W., and Weinberg R.A. Creation of human tumour cells with defined genetic elements. Nature 400 (1999) 464-468
13. Wooten L.G., and Ogretmen B. Sp1/Sp3-dependent regulation of human telomerase reverse transcriptase promoter activity by the bioactive sphingolipid ceramide. J. Biol. Chem. 280 (2005) 28867-28876
14. Dbaibo G.S., Pushkareva M.Y., Jayadev S., Schwarz J.K., Horowitz J.M., Obeid L.M., and Hannun Y.A. Retinoblastoma gene product as a downstream target for a ceramide-dependent pathway of growth arrest. Proc. Natl. Acad. Sci. USA 92 (1995) 1347-1351
15. Dbaibo G.S., Pushkareva M.Y., Rachid R.A., Alter N., Smyth M.J., Obeid L.M., and Hannun Y.A. p53-dependent ceramide response to genotoxic stress. J. Clin. Invest. 102 (1998) 329-339
16. Lee J.Y., Bielawska A.E., and Obeid L.M. Regulation of cyclin-dependent kinase 2 activity by ceramide. Exp. Cell Res. 261 (2000) 303-311
17. Smyth M.J., Perry D.K., Zhang J., Poirier G.G., Hannun Y.A., and Obeid L.M. prICE: a downstream target for ceramide-induced apoptosis and for the inhibitory action of Bcl-2. Biochem. J. 316 Pt 1 (1996) 25-28
18. Thon L., et al. Ceramide mediates caspase-independent programmed cell death. FASEB J. 19 (2005) 1945-1956
19. Taha T.A., Hannun Y.A., and Obeid L.M. Sphingosine kinase: biochemical and cellular regulation and role in disease. J. Biochem. Mol. Biol. 39 (2006) 113-131
20. Hla T. Physiological and pathological actions of sphingosine 1-phosphate. Semin. Cell Dev. Biol. 15 (2004) 513-520
21. Maceyka M., Payne S.G., Milstien S., and Spiegel S. Sphingosine kinase, sphingosine-1-phosphate, and apoptosis. Biochim. Biophys. Acta 1585 (2002) 193-201
22. Rosen H., and Goetzl E.J. Sphingosine 1-phosphate and its receptors: an autocrine and paracrine network. Nat. Rev. Immunol. 5 (2005) 560-570
23. Marchesini N., Luberto C., and Hannun Y.A. Biochemical properties of mammalian neutral sphingomyelinase 2 and its role in sphingolipid metabolism. J. Biol. Chem. 278 (2003) 13775-13783
24. Kolesnick R. The therapeutic potential of modulating the ceramide/sphingomyelin pathway. J. Clin. Invest. 110 (2002) 3-8
25. Bektas M., Jolly P.S., Muller C., Eberle J., Spiegel S., and Geilen C.C. Sphingosine kinase activity counteracts ceramide-mediated cell death in human melanoma cells: role of Bcl-2 expression. Oncogene 24 (2005) 178-187
26. Liu Y.Y., Han T.Y., Giuliano A.E., and Cabot M.C. Ceramide glycosylation potentiates cellular multidrug resistance. FASEB J. 15 (2001) 719-730
27. Riboni L., Campanella R., Bassi R., Villani R., Gaini S.M., Martinelli-Boneschi F., Viani P., and Tettamanti G. Ceramide levels are inversely associated with malignant progression of human glial tumors. Glia 39 (2002) 105-113
28. Rylova S.N., Somova O.G., and Dyatlovitskaya E.V. Comparative investigation of sphingoid bases and fatty acids in ceramides and sphingomyelins from human ovarian malignant tumors and normal ovary. Biochemistry (Mosc) 63 (1998) 1057-1060
29. Guillas I., Kirchman P.A., Chuard R., Pfefferli M., Jiang J.C., Jazwinski S.M., and Conzelmann A. C26-CoA-dependent ceramide synthesis of Saccharomyces cerevisiae is operated by Lag1p and Lac1p. EMBO J. 20 (2001) 2655-2665
30. Schorling S., Vallee B., Barz W.P., Riezman H., and Oesterhelt D. Lag1p and Lac1p are essential for the Acyl-CoA-dependent ceramide synthase reaction in Saccharomyces cerevisae. Mol. Biol. Cell 12 (2001) 3417-3427
31. D'Mello N.P., Childress A.M., Franklin D.S., Kale S.P., Pinswasdi C., and Jazwinski S.M. Cloning and characterization of LAG1, a longevity-assurance gene in yeast. J. Biol. Chem. 269 (1994) 15451-15459
32. Venkataraman K., Riebeling C., Bodennec J., Riezman H., Allegood J.C., Sullards M.C., Merrill Jr. A.H., and Futerman A.H. Upstream of growth and differentiation factor 1 (uog1), a mammalian homolog of the yeast longevity assurance gene 1 (LAG1), regulates N-stearoyl-sphinganine (C18-(dihydro)ceramide) synthesis in a fumonisin B1-independent manner in mammalian cells. J. Biol. Chem. 277 (2002) 35642-35649
33. Riebeling C., Allegood J.C., Wang E., Merrill Jr. A.H., and Futerman A.H. Two mammalian longevity assurance gene (LAG1) family members, trh1 and trh4, regulate dihydroceramide synthesis using different fatty acyl-CoA donors. J. Biol. Chem. 278 (2003) 43452-43459
34. Jiang J.C., Kirchman P.A., Zagulski M., Hunt J., and Jazwinski S.M. Homologs of the yeast longevity gene LAG1 in Caenorhabditis elegans and human. Genome Res. 8 (1998) 1259-1272
35. Kageyama-Yahara, N. and Riezman, H. (2006) Transmembrane topology of ceramide synthase in yeast. Biochem J., In press.
36. Obeid L.M., and Hannun Y.A. Ceramide, stress, and a "LAG" in aging. Sci. Aging Knowledge Environ. 2003 (2003) PE27
37. Guillas I., et al. Human homologues of LAG1 reconstitute Acyl-CoA-dependent ceramide synthesis in yeast. J. Biol. Chem. 278 (2003) 37083-37091
38. Mizutani Y., Kihara A., and Igarashi Y. LASS3 is a mainly testis-specific (dihydro)ceramide synthase with relatively broad substrate specificity. Biochem. J. (2006)
39. Mizutani Y., Kihara A., and Igarashi Y. Mammalian Lass6 and its related family members regulate synthesis of specific ceramides. Biochem. J. 390 (2005) 263-271
40. Lahiri S., and Futerman A.H. LASS5 is a bona fide dihydroceramide synthase that selectively utilizes palmitoyl-CoA as acyl donor. J. Biol. Chem. 280 (2005) 33735-33738
41. Vallee B., and Riezman H. Lip1p: a novel subunit of acyl-CoA ceramide synthase. EMBO J. 24 (2005) 730-741
42. Koybasi S., et al. Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J. Biol. Chem. 279 (2004) 44311-44319
43. Schulz A., et al. The CLN9 protein, a regulator of dihydroceramide synthase. J. Biol. Chem. 281 (2006) 2784-2794
44. Koyanagi S., et al. Elevation of de novo ceramide synthesis in tumor masses and the role of microsomal dihydroceramide synthase. Int. J. Cancer 105 (2003) 1-6
45. Kroesen B.J., Pettus B., Luberto C., Busman M., Sietsma H., de Leij L., and Hannun Y.A. Induction of apoptosis through B-cell receptor cross-linking occurs via de novo generated C16-ceramide and involves mitochondria. J. Biol. Chem. 276 (2001) 13606-13614
46. Eto M., Bennouna J., Hunter O.C., Lotze M.T., and Amoscato A.A. Importance of C16 ceramide accumulation during apoptosis in prostate cancer cells. Int. J. Urol. 13 (2006) 148-156
47. Sullards M.C., Lynch D.V., Merrill Jr. A.H., and Adams J. Structure determination of soybean and wheat glucosylceramides by tandem mass spectrometry. J. Mass Spectrom. 35 (2000) 347-353
48. Pettus B.J., Baes M., Busman M., Hannun Y.A., and Van Veldhoven P.P. Mass spectrometric analysis of ceramide perturbations in brain and fibroblasts of mice and human patients with peroxisomal disorders. Rapid Commun. Mass Spectrom. 18 (2004) 1569-1574
49. Osawa Y., Uchinami H., Bielawski J., Schwabe R.F., Hannun Y.A., and Brenner D.A. Roles for C16-ceramide and sphingosine 1-phosphate in regulating hepatocyte apoptosis in response to tumor necrosis factor-alpha. J. Biol. Chem. 280 (2005) 27879-27887
50. Masukawa Y., Tsujimura H., and Narita H. Liquid chromatography-mass spectrometry for comprehensive profiling of ceramide molecules in human hair. J. Lipid Res. 47 (2006) 1559-1571
51. Sullards M.C., Wang E., Peng Q., and Merrill Jr. A.H. Metabolomic profiling of sphingolipids in human glioma cell lines by liquid chromatography tandem mass spectrometry. Cell Mol. Biol. (Noisy-le-grand) 49 (2003) 789-797
52. Xia P., Gamble J.R., Wang L., Pitson S.M., Moretti P.A., Wattenberg B.W., D'Andrea R.J., and Vadas M.A. An oncogenic role of sphingosine kinase. Curr. Biol. 10 (2000) 1527-1530
53. Van Brocklyn J., Letterle C., Snyder P., and Prior T. Sphingosine-1-phosphate stimulates human glioma cell proliferation through Gi-coupled receptors: role of ERK MAP kinase and phosphatidylinositol 3-kinase beta. Cancer Lett. 181 (2002) 195-204
54. Sarkar S., Maceyka M., Hait N.C., Paugh S.W., Sankala H., Milstien S., and Spiegel S. Sphingosine kinase 1 is required for migration, proliferation and survival of MCF-7 human breast cancer cells. FEBS Lett. 579 (2005) 5313-5317
55. Nava V.E., Hobson J.P., Murthy S., Milstien S., and Spiegel S. Sphingosine kinase type 1 promotes estrogen-dependent tumorigenesis of breast cancer MCF-7 cells. Exp. Cell Res. 281 (2002) 115-127
56. Mizugishi K., Yamashita T., Olivera A., Miller G.F., Spiegel S., and Proia R.L. Essential role for sphingosine kinases in neural and vascular development. Mol. Cell Biol. 25 (2005) 11113-11121
57. Argraves K.M., Wilkerson B.A., Argraves W.S., Fleming P.A., Obeid L.M., and Drake C.J. Sphingosine-1-phosphate signaling promotes critical migratory events in vasculogenesis. J. Biol. Chem. 279 (2004) 50580-50590
58. Chae S.S., Paik J.H., Furneaux H., and Hla T. Requirement for sphingosine 1-phosphate receptor-1 in tumor angiogenesis demonstrated by in vivo RNA interference. J. Clin. Invest. 114 (2004) 1082-1089
59. Taha T.A., Kitatani K., El-Alwani M., Bielawski J., Hannun Y.A., and Obeid L.M. Loss of sphingosine kinase-1 activates the intrinsic pathway of programmed cell death: modulation of sphingolipid levels and the induction of apoptosis. FASEB J. 20 (2006) 482-484
60. Taha T.A., Kitatani K., Bielawski J., Cho W., Hannun Y.A., and Obeid L.M. Tumor necrosis factor induces the loss of sphingosine kinase-1 by a cathepsin B-dependent mechanism. J. Biol. Chem. 280 (2005) 17196-17202
61. El Alwani, M., Wu, B.X., Obeid, L.M. and Hannun, Y.A. (2006) Bioactive sphingolipids in the modulation of the inflammatory response. Pharmacol Ther., In press.
62. Xia P., et al. Sphingosine kinase interacts with TRAF2 and dissects tumor necrosis factor-alpha signaling. J. Biol. Chem. 277 (2002) 7996-8003
63. Pettus B.J., et al. The sphingosine kinase 1/sphingosine-1-phosphate pathway mediates COX-2 induction and PGE2 production in response to TNF-alpha. FASEB J. 17 (2003) 1411-1421
64. Backlund M.G., Mann J.R., and Dubois R.N. Mechanisms for the prevention of gastrointestinal cancer: the role of prostaglandin E2. Oncology 69 Suppl. 1 (2005) 28-32
65. Kawamori T., et al. Sphingosine kinase 1 is up-regulated in colon carcinogenesis. FASEB J. 20 (2006) 386-388
66. Johnson K.R., Johnson K.Y., Crellin H.G., Ogretmen B., Boylan A.M., Harley R.A., and Obeid L.M. Immunohistochemical distribution of sphingosine kinase 1 in normal and tumor lung tissue. J. Histochem. Cytochem. 53 (2005) 1159-1166
67. Lavieu G., Scarlatti F., Sala G., Carpentier S., Levade T., Ghidoni R., Botti J., and Codogno P. Regulation of autophagy by sphingosine kinase 1 and its role in cell survival during nutrient starvation. J. Biol. Chem. 281 (2006) 8518-8527
68. Brinkmann V., Cyster J.G., and Hla T. FTY720: sphingosine 1-phosphate receptor-1 in the control of lymphocyte egress and endothelial barrier function. Am. J. Transplant. 4 (2004) 1019-1025
69. Chun J., and Rosen H. Lysophospholipid receptors as potential drug targets in tissue transplantation and autoimmune diseases. Curr. Pharm. Des. 12 (2006) 161-171
70. Billich A., Bornancin F., Devay P., Mechtcheriakova D., Urtz N., and Baumruker T. Phosphorylation of the immunomodulatory drug FTY720 by sphingosine kinases. J. Biol. Chem. 278 (2003) 47408-47415
71. Paugh S.W., Payne S.G., Barbour S.E., Milstien S., and Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett. 554 (2003) 189-193
72. LaMontagne K., et al. Antagonism of sphingosine-1-phosphate receptors by FTY720 inhibits angiogenesis and tumor vascularization. Cancer Res. 66 (2006) 221-231
73. Bandhuvula P., Tam Y.Y., Oskouian B., and Saba J.D. The immune modulator FTY720 inhibits sphingosine-1-phosphate lyase activity. J. Biol. Chem. 280 (2005) 33697-33700
74. Reiss U., et al. Sphingosine-phosphate lyase enhances stress-induced ceramide generation and apoptosis. J. Biol. Chem. 279 (2004) 1281-1290
75. Modrak D.E., Cardillo T.M., Newsome G.A., Goldenberg D.M., and Gold D.V. Synergistic interaction between sphingomyelin and gemcitabine potentiates ceramide-mediated apoptosis in pancreatic cancer. Cancer Res. 64 (2004) 8405-8410
76. Veldman R.J., Zerp S., van Blitterswijk W.J., and Verheij M. N-hexanoyl-sphingomyelin potentiates in vitro doxorubicin cytotoxicity by enhancing its cellular influx. Br. J. Cancer 90 (2004) 917-925
77. Rossi M.J., et al. Inhibition of growth and telomerase activity by novel cationic ceramide analogs with high solubility in human head and neck squamous cell carcinoma cells. Otolaryngol. Head Neck Surg. 132 (2005) 55-62
78. Novgorodov S.A., Szulc Z.M., Luberto C., Jones J.A., Bielawski J., Bielawska A., Hannun Y.A., and Obeid L.M. Positively charged ceramide is a potent inducer of mitochondrial permeabilization. J. Biol. Chem. 280 (2005) 16096-16105
79. Dindo D., Dahm F., Szulc Z., Bielawska A., Obeid L.M., Hannun Y.A., Graf R., and Clavien P.A. Cationic long-chain ceramide LCL-30 induces cell death by mitochondrial targeting in SW403 cells. Mol. Cancer Ther. 5 (2006) 1520-1529
80. Senkal C.E., et al. Potent antitumor activity of a novel cationic pyridinium-ceramide alone or in combination with gemcitabine against human head and neck squamous cell carcinomas in vitro and in vivo. J. Pharmacol. Exp. Ther. 317 (2006) 1188-1199
81. Modica-Napolitano J.S., and Aprille J.R. Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv. Drug Deliv. Rev. 49 (2001) 63-70
82. Bieberich E., Kawaguchi T., and Yu R.K. N-acylated serinol is a novel ceramide mimic inducing apoptosis in neuroblastoma cells. J. Biol. Chem. 275 (2000) 177-181
83. Struckhoff A.P., Bittman R., Burow M.E., Clejan S., Elliott S., Hammond T., Tang Y., and Beckman B.S. Novel ceramide analogs as potential chemotherapeutic agents in breast cancer. J. Pharmacol. Exp. Ther. 309 (2004) 523-532
84. Crawford K.W., Bittman R., Chun J., Byun H.S., and Bowen W.D. Novel ceramide analogues display selective cytotoxicity in drug-resistant breast tumor cell lines compared to normal breast epithelial cells. Cell Mol. Biol. (Noisy-le-grand) 49 (2003) 1017-1023
85. Stover T., and Kester M. Liposomal delivery enhances short-chain ceramide-induced apoptosis of breast cancer cells. J. Pharmacol. Exp. Ther. 307 (2003) 468-475
86. Stover T.C., Sharma A., Robertson G.P., and Kester M. Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma. Clin. Cancer Res. 11 (2005) 3465-3474
87. Thomas D.A., et al. Phase II study of sphingosomal vincristine in patients with recurrent or refractory adult acute lymphocytic leukemia. Cancer 106 (2006) 120-127
88. Samsel L., et al. The ceramide analog, B13, induces apoptosis in prostate cancer cell lines and inhibits tumor growth in prostate cancer xenografts. Prostate 58 (2004) 382-393
89. Tilly J.L., and Kolesnick R.N. Sphingolipids, apoptosis, cancer treatments and the ovary: investigating a crime against female fertility. Biochim. Biophys. Acta 1585 (2002) 135-138
90. Suomalainen L., Pentikainen V., and Dunkel L. Sphingosine-1-phosphate inhibits nuclear factor kappaB activation and germ cell apoptosis in the human testis independently of its receptors. Am. J. Pathol. 166 (2005) 773-781
91. French K.J., Upson J.J., Keller S.N., Zhuang Y., Yun J.K., and Smith C.D. Antitumor activity of sphingosine kinase inhibitors. J. Pharmacol. Exp. Ther. (2006)
92. Davis M.D., Clemens J.J., Macdonald T.L., and Lynch K.R. Sphingosine 1-phosphate analogs as receptor antagonists. J. Biol. Chem. 280 (2005) 9833-9841
93. Visentin B., et al. Validation of an anti-sphingosine-1-phosphate antibody as a potential therapeutic in reducing growth, invasion, and angiogenesis in multiple tumor lineages. Cancer Cell 9 (2006) 225-238
94. Senchenkov A., Litvak D.A., and Cabot M.C. Targeting ceramide metabolism - a strategy for overcoming drug resistance. J. Natl. Cancer Inst. 93 (2001) 347-357
95. Ogretmen B., and Hannun Y.A. Updates on functions of ceramide in chemotherapy-induced cell death and in multidrug resistance. Drug Resist. Update 4 (2001) 368-377
96. Radin N.S. The development of aggressive cancer: a possible role for sphingolipids. Cancer Invest. 20 (2002) 779-786
97. Hinrichs J.W., Klappe K., and Kok J.W. Rafts as missing link between multidrug resistance and sphingolipid metabolism. J. Membr. Biol. 203 (2005) 57-64
98. Sun Y.L., Zhou G.Y., Li K.N., Gao P., Zhang Q.H., Zhen J.H., Bai Y.H., and Zhang X.F. Suppression of glucosylceramide synthase by RNA interference reverses multidrug resistance in human breast cancer cells. Neoplasma 53 (2006) 1-8
99. Norris-Cervetto E., Callaghan R., Platt F.M., Dwek R.A., and Butters T.D. Inhibition of glucosylceramide synthase does not reverse drug resistance in cancer cells. J. Biol. Chem. 279 (2004) 40412-40418
100. Veldman R.J., et al. The absence of functional glucosylceramide synthase does not sensitize melanoma cells for anticancer drugs. FASEB J. 17 (2003) 1144-1146
101. Gouaze V., Liu Y.Y., Prickett C.S., Yu J.Y., Giuliano A.E., and Cabot M.C. Glucosylceramide synthase blockade down-regulates P-glycoprotein and resensitizes multidrug-resistant breast cancer cells to anticancer drugs. Cancer Res. 65 (2005) 3861-3867
102. Goulding C.W., Giuliano A.E., and Cabot M.C. SDZ PSC 833 the drug resistance modulator activates cellular ceramide formation by a pathway independent of P-glycoprotein. Cancer Lett. 149 (2000) 143-151
103. De Rosa M.F., Sillence D., Ackerley C., and Lingwood C. Role of multiple drug resistance protein 1 in neutral but not acidic glycosphingolipid biosynthesis. J. Biol. Chem. 279 (2004) 7867-7876
104. Gouaze V., et al. Overexpression of glucosylceramide synthase and P-glycoprotein in cancer cells selected for resistance to natural product chemotherapy. Mol. Cancer Ther. 3 (2004) 633-639
105. Hinrichs J.W., Klappe K., Hummel I., and Kok J.W. ATP-binding cassette transporters are enriched in non-caveolar detergent-insoluble glycosphingolipid-enriched membrane domains (DIGs) in human multidrug-resistant cancer cells. J. Biol. Chem. 279 (2004) 5734-5738
106. Hinrichs J.W., Klappe K., van Riezen M., and Kok J.W. Drug resistance-associated changes in sphingolipids and ABC transporters occur in different regions of membrane domains. J. Lipid Res. 46 (2005) 2367-2376
107. Pchejetski D., et al. Sphingosine kinase-1 as a chemotherapy sensor in prostate adenocarcinoma cell and mouse models. Cancer Res. 65 (2005) 11667-11675
108. Alexander S., Min J., and Alexander H. Dictyostelium discoideum to human cells: pharmacogenetic studies demonstrate a role for sphingolipids in chemoresistance. Biochim. Biophys. Acta 1760 (2006) 301-309
109. Min J., Van Veldhoven P.P., Zhang L., Hanigan M.H., Alexander H., and Alexander S. Sphingosine-1-phosphate lyase regulates sensitivity of human cells to select chemotherapy drugs in a p38-dependent manner. Mol. Cancer Res. 3 (2005) 287-296
110. Akao Y., Banno Y., Nakagawa Y., Hasegawa N., Kim T.J., Murate T., Igarashi Y., and Nozawa Y. High expression of sphingosine kinase 1 and S1P receptors in chemotherapy-resistant prostate cancer PC3 cells and their camptothecin-induced up-regulation. Biochem. Biophys. Res. Commun. 342 (2006) 1284-1290
111. Wang H., Maurer B.J., Reynolds C.P., and Cabot M.C. N-(4-hydroxyphenyl)retinamide elevates ceramide in neuroblastoma cell lines by coordinate activation of serine palmitoyltransferase and ceramide synthase. Cancer Res. 61 (2001) 5102-5105
112. Maurer B.J., Melton L., Billups C., Cabot M.C., and Reynolds C.P. Synergistic cytotoxicity in solid tumor cell lines between N-(4-hydroxyphenyl)retinamide and modulators of ceramide metabolism. J. Natl. Cancer Inst. 92 (2000) 1897-1909
113. Maurer B.J., Metelitsa L.S., Seeger R.C., Cabot M.C., and Reynolds C.P. Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines. J. Natl. Cancer Inst. 91 (1999) 1138-1146
114. Borek C., and Merrill Jr. A.H. Sphingolipids inhibit multistage carcinogenesis and protein kinase C. Basic Life Sci. 61 (1993) 367-371
115. Schmelz E.M., Dillehay D.L., Webb S.K., Reiter A., Adams J., and Merrill Jr. A.H. Sphingomyelin consumption suppresses aberrant colonic crypt foci and increases the proportion of adenomas versus adenocarcinomas in CF1 mice treated with 1,2-dimethylhydrazine: implications for dietary sphingolipids and colon carcinogenesis. Cancer Res. 56 (1996) 4936-4941
116. Schmelz E.M., Sullards M.C., Dillehay D.L., and Merrill Jr. A.H. Colonic cell proliferation and aberrant crypt foci formation are inhibited by dairy glycosphingolipids in 1,2-dimethylhydrazine-treated CF1 mice. J. Nutr. 130 (2000) 522-527
117. Scarlatti F., Sala G., Somenzi G., Signorelli P., Sacchi N., and Ghidoni R. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J. 17 (2003) 2339-2341
118. Minutolo F., et al. Synthesis of a resveratrol analogue with high ceramide-mediated proapoptotic activity on human breast cancer cells. J. Med. Chem. 48 (2005) 6783-6786
119. Herrera B., Carracedo A., Diez-Zaera M., Gomez Del Pulgar T., Guzman M., and Velasco G. The CB2 cannabinoid receptor signals apoptosis via ceramide-dependent activation of the mitochondrial intrinsic pathway. Exp. Cell Res. 312 (2006) 2121-2131
120. Jiang Q., Wong J., Fyrst H., Saba J.D., and Ames B.N. gamma-Tocopherol or combinations of vitamin E forms induce cell death in human prostate cancer cells by interrupting sphingolipid synthesis. Proc. Natl. Acad. Sci. USA 101 (2004) 17825-17830
121. Hu W., Xu R., Zhang G., Jin J., Szulc Z.M., Bielawski J., Hannun Y.A., Obeid L.M., and Mao C. Golgi fragmentation is associated with ceramide-induced cellular effects. Mol. Biol. Cell 16 (2005) 1555-1567
122. Hanada K., Kumagai K., Yasuda S., Miura Y., Kawano M., Fukasawa M., and Nishijima M. Molecular machinery for non-vesicular trafficking of ceramide. Nature 426 (2003) 803-809
123. Giussani P., Maceyka M., Le Stunff H., Mikami A., Lepine S., Wang E., Kelly S., Merrill Jr. A.H., Milstien S., and Spiegel S. Sphingosine-1-phosphate phosphohydrolase regulates endoplasmic reticulum-to-golgi trafficking of ceramide. Mol. Cell Biol. 26 (2006) 5055-5069
124. Ogretmen B., et al. Biochemical mechanisms of the generation of endogenous long chain ceramide in response to exogenous short chain ceramide in the A549 human lung adenocarcinoma cell line. Role for endogenous ceramide in mediating the action of exogenous ceramide. J. Biol. Chem. 277 (2002) 12960-12969
125. Sultan I., Senkal C.E., Ponnusamy S., Bielawski J., Szulc Z., Bielawska A., Hannun Y.A., and Ogretmen B. Regulation of the sphingosine-recycling pathway for ceramide generation by oxidative stress, and its role in controlling c-Myc/Max function. Biochem. J. 393 (2006) 513-521
126. Valaperta R., Chigorno V., Basso L., Prinetti A., Bresciani R., Preti A., Miyagi T., and Sonnino S. Plasma membrane production of ceramide from ganglioside GM3 in human fibroblasts. FASEB J. 20 (2006) 1227-1229
127. Schmelz E.M. Sphingolipids in the chemoprevention of colon cancer. Front Biosci. 9 (2004) 2632-2639
128. Han X., and Cheng H. Characterization and direct quantitation of cerebroside molecular species from lipid extracts by shotgun lipidomics. J. Lipid Res. 46 (2005) 163-175
129. Ivleva V.B., Elkin Y.N., Budnik B.A., Moyer S.C., O'Conner P.B., and Costello C.E. Coupling thin-layer chromatography with vibrational cooling matrix-assisted laser desorption/ionization Fourier transform mass spectrometry for the analysis of ganglioside mixtures. Anal. Chem. 76 (2004) 6484-6491
130. Meisen I., Friedrich A.W., Karch H., Witting U., Peter-Katalinic J., and Muthing J. Application of combined high-performance thin-layer chromatography immunostaining and nanoelectrospray ionization quadrupole time-of-flight tandem mass spectrometry to the structural characterization of high- and low-affinity binding ligands of Shiga toxin 1. Rapid Commun. Mass Spectrom. 19 (2005) 3659-3665
131. Merrill Jr. A.H., Sullards M.C., Allegood J.C., Kelly S., and Wang E. Sphingolipidomics: high-throughput, structure-specific, and quantitative analysis of sphingolipids by liquid chromatography tandem mass spectrometry. Methods 36 (2005) 207-224
132. Vukelic Z., Zamfir A.D., Bindila L., Froesch M., Peter-Katalinic J., Usuki S., and Yu R.K. Screening and sequencing of complex sialylated and sulfated glycosphingolipid mixtures by negative ion electrospray Fourier transform ion cyclotron resonance mass spectrometry. J. Am. Soc. Mass Spectrom. 16 (2005) 571-580
133. Wang G., Silva J., Krishnamurthy K., Tran E., Condie B.G., and Bieberich E. Direct binding to ceramide activates protein kinase Czeta before the formation of a pro-apoptotic complex with PAR-4 in differentiating stem cells. J. Biol. Chem. 280 (2005) 26415-26424